• About
  • Masthead
  • License Content
  • Advertise
  • Submit Press Release
  • RSS/Email List
  • Write for us
  • Contact us
2 Minute Medicine
No Result
View All Result

No products in the cart.

SUBSCRIBE
  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • The Scan
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • AccountLog-in/out
    • Subscribe
    • Sign-in
    • My account
2 Minute Medicine
  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • The Scan
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • AccountLog-in/out
    • Subscribe
    • Sign-in
    • My account
SUBSCRIBE
2 Minute Medicine
Subscribe
Home The Classics Hematology/Oncology Classics

Stereotactic body radiotherapy as a state of the art treatment option in inoperable non-small cell lung cancer [Classics Series]

byDeepti Shroff Karhade
July 2, 2022
in Hematology/Oncology Classics, The Classics
Reading Time: 3 mins read
0
Share on FacebookShare on Twitter

This study summary is an excerpt from the book 2 Minute Medicine’s The Classics in Medicine: Summaries of the Landmark Trials

1. Stereotactic body radiotherapy (SBRT) achieved a 3 year local tumor control rate of 92% with limited toxicity, making SBRT a valuable treatment option in inoperable (and potentially even operable) patients

Original Date of Publication: July 2009

Study Rundown: Lung cancer is the most common cancer worldwide, and non-small cell lung cancer (NSCLC) accounts for the majority of cases. Surgical resection remains the mainstay of treatment for patients with stage I NSCLC approved for surgery. Historically, medically inoperable patients with NSCLC were managed with radiation therapy (RT) and showed poor five-year survival rates, presumably from insufficient doses. Phase II trials, however, have shown that SBRT – a method using precise targeted radiation to minimize radiation to adjacent tissue – produces tumor control rates even higher than surgical intervention. SBRT can thus administer biologic doses up to twice as high as RT without harmful affects to normal tissue. Though studies have shown good rates of local tumor control and toxicity for SBRT, the vast majority have been retrospective. Given the paucity of prospective trials and the lack of long-term follow-up data, application of SBRT remains limited.  This multicenter prospective phase II study assessed the 36 month survival of NSCLC and evaluated tumor control, survival, and toxicity based on SBRT. The results indicate a tumor control rate similar to surgery in operative cases, a favorable 3 year cancer specific-survival rate, and minimal toxicity. The later Radiation Therapy Oncology Group (RTOG) 0236 trial from Timmerman et al. reported an even high rate of primary tumor control with minimal toxicity. It is noted that the optimal dose and schedule for SBRT is still undefined for treating NSCLC.

Click to read the study in the Journal of Clinical Oncology

In-Depth [prospective cohort]: This prospective phase II study recruited 60 patients with medically inoperable stage I NSCLC, mainly due to COPD (60%) or cardiovascular disease (25%) across 7 centers in Nordic countries. Patients with prior malignancy or a primary tumor next to the trachea, main bronchus, or esophagus were excluded to ensure safety. After patients were referred to RT units, two were excluded based on insufficient radiation dose and one was lost to follow-up. The remaining 57 patients with NSCLC (70% T1N0M0 and 30% T2N0M0) were treated with SBRT using 6 MV from a linear accelerator, after defining the gross tumor volume (GTV, the size of the macroscopic tumor), clinical target volume (CTV, the volume of microscopic and gross malignant tissue), and planning target volume (PTV, the CTV plus a margin of safety around the tumor). CT was performed before each treatment to verify target reproducibility. Patients were then assessed with toxicity grading and chest CT or x-ray at 6 weeks, every 3 months for the first 18 months, and at 24 and 36 months following treatment. Lung function was measured at 3, 9, and 18 months using the Karnofsky performance score. After the study’s conclusion at 36 months, the Kaplan-Meier estimated progression-free survival rate was 52%. The lung cancer-specific survival rates at 1, 2, and 3 years were 93%, 88%, and 88%, respectively. The Kaplan-Meier estimated local tumor control at 3 years was 92%. Four patients (7%), all with T2N0M0 tumors, showed local tumor progression. No patient was lethally affected by SBRT and 14 patients (25%) had no pulmonary adverse effects.

Baumann P, Nyman J, Hoyer M, Wennberg B, Gagliardi G, Lax I, et al. Outcome in a Prospective Phase II Trial of Medically Inoperable Stage I Non–Small-Cell Lung Cancer Patients Treated With Stereotactic Body Radiotherapy. JCO. 2009 Jul 10;27(20):3290–6.

RELATED REPORTS

#VisualAbstract: Intensity-modulated radiotherapy alone is noninferior to concurrent chemoradiotherapy for low-risk nasopharyngeal carcinoma

Toripalimab addition to chemotherapy showed improved survival in advanced stage non-small-cell lung cancer

#VisualAbstract: Adjuvant pembrolizumab increased disease-free survival in completely resected, PD-L1 unselected non-small-cell lung cancer patients

Additional Review:

Timmerman R, Paulus R, Galvin J, Michalski J, Straube W, Bradley J, et al. Stereotactic Body Radiation Therapy for Inoperable Early Stage Lung Cancer. JAMA. 2010 Mar 17;303(11):1070–6.

©2022 2 Minute Medicine, Inc. All rights reserved. No works may be reproduced without expressed written consent from 2 Minute Medicine, Inc. Inquire about licensing here. No article should be construed as medical advice and is not intended as such by the authors or by 2 Minute Medicine, Inc.

Tags: cancer survivalnon-small cell lung cancer (NSCLC)radiotherapytumor control
Previous Post

Health system-based care associated with better treatment use and high rates of tobacco abstinence at 3 months post-discharge in hospitalized smokers

Next Post

2 Minute Medicine Rewind July 4, 2022

RelatedReports

#VisualAbstract: Intensity-modulated radiotherapy alone is noninferior to concurrent chemoradiotherapy for low-risk nasopharyngeal carcinoma
StudyGraphics

#VisualAbstract: Intensity-modulated radiotherapy alone is noninferior to concurrent chemoradiotherapy for low-risk nasopharyngeal carcinoma

October 25, 2022
Patient Basics: Squamous Cell Carcinoma of the Lung
Oncology

Toripalimab addition to chemotherapy showed improved survival in advanced stage non-small-cell lung cancer

October 17, 2022
#VisualAbstract: Adjuvant pembrolizumab increased disease-free survival in completely resected, PD-L1 unselected non-small-cell lung cancer patients
StudyGraphics

#VisualAbstract: Adjuvant pembrolizumab increased disease-free survival in completely resected, PD-L1 unselected non-small-cell lung cancer patients

September 28, 2022
Oophorectomy associated with reduced cancer risk and all-cause mortality for BRCA1/2 patients
Oncology

Selpercatinib continues to demonstrate effective response in RET fusion-positive NSCLC

September 26, 2022
Next Post
Patients with low back pain or pain at multiple sites at highest risk for chronic opioid use

2 Minute Medicine Rewind July 4, 2022

Quick Take: Intravenous patient-controlled analgesia versus thoracic epidural analgesia after open liver surgery

Early initiation of poststernotomy cardiac rehabilitation exercise training is effective and safe

FOLFOX combined with nivolumab and trastuzumab in ERBB2-positive esophagogastric adenocarcinoma is an emerging therapy option

License Our Award-Winning Physician-Written Medical News and Visual Abstracts

2 Minute Medicine is the leading authoritative medical news licensing service, and the only with reports written by practicing doctors.

LICENSE CONTENT

2MM+ Premium Access

No ads & unlimited access to all current reports, over 9000 searchable archived reports, visual abstracts, Weekly Rewinds, and the online edition of The Classics Series™ textbook.

Subscription Options
2 Minute Medicine

2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.

Recent Reports

  • Cystatin C-based equation without race or sex improves accuracy of GFR estimation
  • #VisualAbstract: Aldosterone synthase inhibition reduced systolic blood pressure in patients with treatment-resistant hypertension
  • High-dose exercise therapy is not superior to low-dose exercise therapy for knee osteoarthritis
License Content
Terms of Use | Disclaimer
Cookie Policy
Privacy Statement (EU)
Disclaimer

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.

  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • The Scan
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.

Want more physician-written
medical news?

Join over 10 million yearly readers and numerous companies. For healthcare professionals
and the public.

Subscribe for free today!

Subscription options